We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy.
- Authors
Wang, Yuqing; Du, Jiang; Gao, Zhenyue; Sun, Haoyang; Mei, Mei; Wang, Yu; Ren, Yu; Zhou, Xuan
- Abstract
Immune checkpoint blockade therapy targeting programmed cell death protein 1 (PD-1) has revolutionized the landscape of multiple human cancer types, including head and neck squamous carcinoma (HNSCC). Programmed death ligand-2 (PD-L2), a PD-1 ligand, mediates cancer cell immune escape (or tolerance independent of PD-L1) and predicts poor prognosis of patients with HNSCC. Therefore, an in-depth understanding of the regulatory process of PD-L2 expression may stratify patients with HNSCC to benefit from anti-PD-1 immunotherapy. In this review, we summarised the PD-L2 expression and its immune-dependent and independent functions in HNSCC and other solid tumours. We focused on recent findings on the mechanisms that regulate PD-L2 at the genomic, transcriptional, post-transcriptional, translational, and post-translational levels, also in intercellular communication of tumour microenvironment (TME). We also discussed the prospects of using small molecular agents indirectly targeting PD-L2 in cancer therapy. These findings may provide a notable avenue in developing novel and effective PD-L2-targeted therapeutic strategies for immune combination therapy and uncovering biomarkers that improve the clinical efficacy of anti-PD-1 therapies.
- Publication
British Journal of Cancer, 2023, Vol 128, Issue 7, p1196
- ISSN
0007-0920
- Publication type
Article
- DOI
10.1038/s41416-022-02084-y